BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis

In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF V600E by allele-specific real-time PCR (AS-PCR). Positive results were confirmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Rustad, E H, Dai, H Y, Hov, H, Coward, E, Beisvag, V, Myklebost, O, Hovig, E, Nakken, S, Vodák, D, Meza-Zepeda, L A, Sandvik, A K, Wader, K F, Misund, K, Sundan, A, Aarset, H, Waage, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382665/
https://www.ncbi.nlm.nih.gov/pubmed/25794135
http://dx.doi.org/10.1038/bcj.2015.24

Ejemplares similares

Ejemplares similares